- In April 2024 Shilpa Medicare's marketing partner, Amneal Pharmaceuticals, has launched PEMRYDI RTU (Pemetrexed injection 10 mg/mL), the first ready-to-use formulation of pemetrexed in the U.S. market. This product has received a permanent J-code (J9324) from the U.S. Centers for Medicare & Medicaid Services (CMS). Pemetrexed injection is primarily used in the treatment of non-small cell lung cancer, in combination with other chemotherapy agents, and is also indicated for treating mesothelioma alongside cisplatin
- In September 2024, Merck & Co. Inc. announced that the U.S. Food and Drug Administration (FDA) approved its blockbuster cancer drug, Keytruda, for the treatment of malignant pleural mesothelioma, a rare cancer linked to asbestos exposure. This approval marks a significant advancement in treatment options for this aggressive form of cancer. Keytruda's expanded use offers new hope for patients affected by this life-threatening disease
- In April 2024, Amneal Pharmaceuticals announced the launch of PEMRYDI RTU, the first and only ready-to-use formulation of pemetrexed for injection. Unlike other versions, this product requires no reconstitution, dilution, or refrigeration, offering a more convenient alternative for healthcare providers. The ready-to-use format simplifies preparation and administration compared to existing pemetrexed options
- In Dec 2022, Eagle Pharmaceuticals' Pemfexy, a treatment for non-small cell lung cancer and mesothelioma, has received approval for its fifth indication, aligning it with the approved uses of Eli Lilly's Alimta. This milestone expands the therapeutic applications of Pemfexy, enhancing its utility in oncology. The approval underscores Pemfexy's role as a valuable alternative in the treatment landscape for these challenging cancers
